|

UAE Inhibitor TAK-243 Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since May 2026

Also known as: AOB87172, MLN7243, TAK-243

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Indolent Non-Hodgkin Lymphoma1
  • Advanced Lymphoma1
  • Refractory Malignant Solid Neoplasm1
  • Recurrent Malignant Solid Neoplasm1
  • Metastatic Malignant Solid Neoplasm1

Bethesda, Maryland1 trial

Studying TAK-243 in Patients With Advanced Cancer

National Cancer Institute Developmental Therapeutics Clinic

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.